E
Eidos Therapeutics
Improve and prolong the lives of patients suffering from transthyretin amyloidosis
About Eidos Therapeutics
Eidos Therapeutics, a subsidiary of BridgeBio, operates in the healthcare sector, specifically in the research and development of treatments for a rare disease known as Transthyretin (TTR) amyloidosis (ATTR). This disease, which can severely damage the heart and/or nervous system, is currently underdiagnosed and has limited treatment options. Eidos Therapeutics aims to improve the life expectancy and quality of life for patients suffering from ATTR by developing a novel therapeutic.
Read full description
The company's research focuses on TTR, a protein found in all vertebrates that plays a crucial role in the transport of thyroxine and vitamin A. It is believed to have a role in preserving cognitive function. A form of amyloidosis, ATTR cardiomyopathy (ATTR-CM), is caused by the destabilization of TTR and the subsequent accumulation of misfolded TTR protein in the myocardium, a muscle tissue in the heart. This condition can significantly impair a patient's quality of life and life expectancy.
Eidos Therapeutics' business model revolves around the discovery and development of treatments for ATTR. The company's primary clients are patients suffering from this disease. The company generates revenue through the development and sale of these treatments.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Palo Alto, United States
- Employees
- 53
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Eidos Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2018 | $64M | $256M | Aisling Capital · Viking Global Investors · Janus Henderson · Perceptive Advisors | — |
| SERIES AOther financing | Sep 2017 | $27M | $108M | BridgeBio | — |
Growth signals
Latest recorded traffic for Eidos Therapeutics is 500 monthly website visits, down 33.3% over the last three months. Eidos Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
BridgeBio
RA Capital Management
Aisling Capital
Viking Global Investors- JHJanus Henderson
Perceptive Advisors
Cormorant Asset Management
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eidos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eidos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.